BioXcel Therapeutics
BTAI
BTAI
85 hedge funds and large institutions have $25.8M invested in BioXcel Therapeutics in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 34 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
38% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 34
78% less capital invested
Capital invested by funds: $118M → $25.8M (-$92M)
Holders
85
Holding in Top 10
–
Calls
$1.09M
Puts
$835K
Top Buyers
| 1 | +$1.09M | |
| 2 | +$807K | |
| 3 | +$763K | |
| 4 |
Millennium Management
New York
|
+$373K |
| 5 |
Morgan Stanley
New York
|
+$279K |
Top Sellers
| 1 | -$5.95M | |
| 2 | -$4.43M | |
| 3 | -$4.23M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.21M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$4.15M |